Lioness Associates, Inc.

Economic & Corporate Risk/Yield Reports

October 30, 2012  -- Alnylam Risk/Yield Update for 2012

Refer to Reading Graphs for information on interpretation of the graphs.

Alnylam stock price has been drifting down since a high of 21+ in September. The ALNY 2012 Risk/Yield graph along with the ALNY 2012 Total Risk/Yield graph indicate that there is likely to be more activity with this stock near the end of the year.  Note, the global and USA trends indicate that there may be pressure at about the same time possibly due to the "fiscal cliff" and as a result, may have little movement in Alnylam's chart.

Astrological configurations that are shaping up for later this year and into next year could indicate either significant research progress or the interest of larger companies. This is one to watch until the spring/summer of 2013.


July 18, 2012  -- Alnylam Pharmaceuticals Risk/Yield for 2012

Alnylam Pharmaceuticals moved sharply higher this week on the release of Phase I trial data (see article).  With the move higher, I sold my position out but, may revisit this stock later in the year.

The ALNY Risk/Yield 2012 graph depicts that the data points are predominantly yield rather than risk thruout the year. The period in July 2012 has a delta core of 0 and indicates a pulling between the risk and yield core data points which could result in some turbulence for the stock price until it stabilizes with slightly more yield data points as it moves into August.

The ALNY Delta Core/Transient 2012 graph illustrates that the core stays in yield but, does not go above the 400 level except at the March 2012 period. 

The last graph, the ALNY Total Risk/Yield Activity 2012 graph illustrates a high point in March, another high point in July and a third high point later in the year.  The high point in July shown in this graph along with the delta core value of 0 from the previous graph indicates that July could have some price volatility.  An interesting observation is the high point later in the year. At that period, the USA economy is apt to do better later in the year (see home page) and this activity spike could be from that or it could be another news-worthy item for this company. 

We'll revisit this company in a few months and update.  


Disclosure as of 7/18/2012 - Alnylam Pharmaceuticals (ALNY) is not part of our portfolio at this time.